Pauline De Kinderen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pauline De Kinderen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Josephina A. N. Meester
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
2 shared publications Aline Verstraeten
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
1 shared publication- Aline Verstraeten
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
1 shared publication Bart L. Loeys
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
1 shared publication- Bart Loeys
University of Antwerp
1 shared publication - Silke Peeters
University of Antwerp/Antwerp University Hospital
1 shared publication
Latest Publications
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 322 (6) , C1214-C1222
The role of biglycan in the healthy and thoracic aneurysmal aorta
The class I small leucine-rich proteoglycan biglycan is a crucial structural extracellular matrix component that interacts with a wide range of extracellular matrix molecules. In addition, biglycan is involved in sequestering growth factors such as transforming growth factor-β and bone morphogenetic proteins and thereby regulating pathway activity. Biglycan consists of a 42-kDa core protein linked to two glycosaminoglycan side chains and both are involved in protein interactions. Biglycan is encoded by the BGN gene located on the X-chromosome and is expressed in various tissues, including vascular tissue, skin, brain, kidney, lung, the immune system, and the musculoskeletal system. Although an increasing amount of data on the biological function of biglycan in the vasculature has been produced, its role in thoracic aortic aneurysms is still not fully elucidated. This review focuses on the role of biglycan in the healthy thoracic aorta and the development of thoracic aortic aneurysm and dissections in both mice and humans.
- 1 June 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 322 (6) , C1214-C1222
The role of biglycan in the healthy and thoracic aneurysmal aorta
The class I small leucine-rich proteoglycan biglycan is a crucial structural extracellular matrix component that interacts with a wide range of extracellular matrix molecules. In addition, biglycan is involved in sequestering growth factors such as transforming growth factor-β and bone morphogenetic proteins and thereby regulating pathway activity. Biglycan consists of a 42-kDa core protein linked to two glycosaminoglycan side chains and both are involved in protein interactions. Biglycan is encoded by the BGN gene located on the X-chromosome and is expressed in various tissues, including vascular tissue, skin, brain, kidney, lung, the immune system, and the musculoskeletal system. Although an increasing amount of data on the biological function of biglycan in the vasculature has been produced, its role in thoracic aortic aneurysms is still not fully elucidated. This review focuses on the role of biglycan in the healthy thoracic aorta and the development of thoracic aortic aneurysm and dissections in both mice and humans.
- Open Access
- 28 April 2022
- Published by Wiley in Human Mutation
- Vol. 43 (7) , 815-831
The fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2
Different pathogenic variants in the fibrillin‐1 gene (FBN1) cause Marfan syndrome and acromelic dysplasias. Whereas the musculoskeletal features of Marfan syndrome involve tall stature, arachnodactyly, joint hypermobility, and muscle hypoplasia, acromelic dysplasia patients present with short stature, brachydactyly, stiff joints, and hypermuscularity. Similarly, pathogenic variants in the fibrillin‐2 gene (FBN2) cause either a Marfanoid congenital contractural arachnodactyly or a FBN2‐related acromelic dysplasia that most prominently presents with brachydactyly. The phenotypic and molecular resemblances between both the FBN1 and FBN2‐related disorders suggest that reciprocal pathomechanistic lessons can be learned. In this review, we provide an updated overview and comparison of the phenotypic and mutational spectra of both the “tall” and “short” fibrillinopathies. The future parallel functional study of both FBN1/2‐related disorders will reveal new insights into how pathogenic fibrillin variants differently affect the fibrillin microfibril network and/or growth factor homeostasis in clinically opposite syndromes. This knowledge may eventually be translated into new therapeutic approaches by targeting or modulating the fibrillin microfibril network and/or the signaling pathways under its control.
- 28 April 2022
- Published by Wiley in Human Mutation
- Vol. 43 (7) , 815-831
Open AccessThe fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2
Different pathogenic variants in the fibrillin‐1 gene (FBN1) cause Marfan syndrome and acromelic dysplasias. Whereas the musculoskeletal features of Marfan syndrome involve tall stature, arachnodactyly, joint hypermobility, and muscle hypoplasia, acromelic dysplasia patients present with short stature, brachydactyly, stiff joints, and hypermuscularity. Similarly, pathogenic variants in the fibrillin‐2 gene (FBN2) cause either a Marfanoid congenital contractural arachnodactyly or a FBN2‐related acromelic dysplasia that most prominently presents with brachydactyly. The phenotypic and molecular resemblances between both the FBN1 and FBN2‐related disorders suggest that reciprocal pathomechanistic lessons can be learned. In this review, we provide an updated overview and comparison of the phenotypic and mutational spectra of both the “tall” and “short” fibrillinopathies. The future parallel functional study of both FBN1/2‐related disorders will reveal new insights into how pathogenic fibrillin variants differently affect the fibrillin microfibril network and/or growth factor homeostasis in clinically opposite syndromes. This knowledge may eventually be translated into new therapeutic approaches by targeting or modulating the fibrillin microfibril network and/or the signaling pathways under its control.